Article type
Abstract
Background:
Despite advancements in medicine, myocardial infarction (MI) remains a significant public health burden in Korea. While established guidelines exist globally, tailoring pharmacotherapy recommendations to the local context is crucial. This study aimed to effectively communicate and disseminate evidence-based pharmacotherapy guidelines for MI in Korea.
Objectives:
Effectively communicate and disseminate evidence-based pharmacotherapy guidelines for MI in Korea to ensure their clinical impact and improve patient outcomes.
Methods:
We employed a multifaceted approach to gather expert feedback and enhance guideline accessibility. Two symposiums and external reviews by 8 advisory committee members and 2 methodology experts ensured clinical and methodological rigor. We also considered patient values and preferences through a systematic review of relevant studies. Infographics and treatment flowcharts were developed to visualize key recommendations and facilitate understanding for diverse audiences.
Results:
The symposiums facilitated engagement with cardiologists, shaping the subsequent revision of the guidelines. The advisory committees and methodology experts provided valuable feedback, strengthening the recommendations. Eight of the recommendations were found to be agreed upon by the external experts, and only one was found to be unclear. As a PICO-based systematic review of 21 studies, we categorized findings as drug preferences, treatment types, desired outcomes, and overall patient priorities. This patient-centered analysis directly informed and shaped the final recommendations. Infographics and flowcharts were created, aiding comprehension and promoting guideline adoption.
Conclusions:
This study successfully implemented a multifaceted strategy for Korean MI pharmacotherapy guidelines, securing expert input, increasing accessibility, and facilitating implementation. However, a primarily cardiologist-focused approach underscored the importance for broader stakeholder engagement, including direct patient involvement, to further optimize future versions and maximize impact.
Despite advancements in medicine, myocardial infarction (MI) remains a significant public health burden in Korea. While established guidelines exist globally, tailoring pharmacotherapy recommendations to the local context is crucial. This study aimed to effectively communicate and disseminate evidence-based pharmacotherapy guidelines for MI in Korea.
Objectives:
Effectively communicate and disseminate evidence-based pharmacotherapy guidelines for MI in Korea to ensure their clinical impact and improve patient outcomes.
Methods:
We employed a multifaceted approach to gather expert feedback and enhance guideline accessibility. Two symposiums and external reviews by 8 advisory committee members and 2 methodology experts ensured clinical and methodological rigor. We also considered patient values and preferences through a systematic review of relevant studies. Infographics and treatment flowcharts were developed to visualize key recommendations and facilitate understanding for diverse audiences.
Results:
The symposiums facilitated engagement with cardiologists, shaping the subsequent revision of the guidelines. The advisory committees and methodology experts provided valuable feedback, strengthening the recommendations. Eight of the recommendations were found to be agreed upon by the external experts, and only one was found to be unclear. As a PICO-based systematic review of 21 studies, we categorized findings as drug preferences, treatment types, desired outcomes, and overall patient priorities. This patient-centered analysis directly informed and shaped the final recommendations. Infographics and flowcharts were created, aiding comprehension and promoting guideline adoption.
Conclusions:
This study successfully implemented a multifaceted strategy for Korean MI pharmacotherapy guidelines, securing expert input, increasing accessibility, and facilitating implementation. However, a primarily cardiologist-focused approach underscored the importance for broader stakeholder engagement, including direct patient involvement, to further optimize future versions and maximize impact.